Oncology Biosimilars Market Research Report: Size, Share, Trend Analysis By Product Type (Monoclonal Antibodies, Proteins, Peptides, Vaccines), By Therapeutic Area (Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Leukemia), By Route of Administration (Intravenous, Subcutaneous, Oral), By End Users (Hospitals, Specialty Clinics, Research Laboratories) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
Global Oncology Biosimilars Market Size was valued at USD 5.469 Billion in 2024 & the market is projected to grow from USD 5.973 Billion in 2025 to USD 14.4 Billion by 2035, registering a CAGR of 9.00% during the forecast period 2025–2035. North America led the market with over 45.71% share, generating around USD 2.5 Billion in revenue. The increasing global cancer burden and growing demand for cost-effective biologic therapies are accelerating the Oncology Biosimilars Market. Expanding regulatory support, patent expirations of blockbuster biologics, and broader physician acceptance are improving patient access while reducing oncology treatment costs across healthcare systems. According to the WHO Data Portal, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022, highlighting the growing need for affordable oncology treatments, including biosimilars that expand patient access to life-saving biologic therapies.
The Oncology Biosimilars Market is poised for substantial growth driven by increasing demand for cost-effective therapies and supportive regulatory frameworks.
| 2024 Market Size | 5.469 (USD Billion) |
| 2035 Market Size | 14.4 (USD Billion) |
| CAGR (2025 - 2035) | 9.2% |
Companies such as Amgen(US), Roche (CH), Sandoz (CH), Pfizer (US), Boehringer Ingelheim (DE), Mylan (US), Celltrion (KR), Samsung Bioepis (KR), Teva (IL) are some of the major participants in the market.
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The Oncology Biosimilars Market is currently experiencing a notable transformation, driven by increasing demand for cost-effective treatment options and the growing prevalence of cancer worldwide. As healthcare systems strive to manage expenses while ensuring patient access to essential therapies, biosimilars are emerging as a viable alternative to expensive biologics. This shift is further supported by regulatory frameworks that are becoming more favorable towards the approval and commercialization of biosimilars, thereby enhancing market dynamics.
Additionally, the rising awareness among healthcare professionals and patients regarding the efficacy and safety of biosimilars is likely to bolster their adoption in clinical settings. Moreover, the Oncology Biosimilars Market appears to be influenced by advancements in biotechnology and manufacturing processes, which may lead to improved product quality and consistency. The competitive landscape is evolving, with numerous pharmaceutical companies entering the biosimilars arena, indicating a robust pipeline of new products. This influx of innovation could potentially enhance treatment options available to oncologists and patients alike. As the market continues to mature, it is essential to monitor the interplay between regulatory developments, market access strategies, and the overall acceptance of biosimilars within oncology treatment paradigms.
The Oncology Biosimilars Market is witnessing an increasing demand for affordable treatment alternatives. As healthcare costs escalate, stakeholders are seeking ways to provide effective therapies without imposing financial burdens on patients. This trend is likely to drive the growth of biosimilars, as they offer similar therapeutic benefits at reduced prices.
Regulatory bodies are enhancing their frameworks to facilitate the approval of biosimilars, which may lead to a more streamlined process for market entry. This evolving landscape suggests that the Oncology Biosimilars Market could see a surge in new product launches, as companies navigate these supportive regulations to bring their offerings to market.
There is a noticeable increase in awareness regarding the safety and efficacy of biosimilars among healthcare professionals and patients. This growing acceptance may contribute to a shift in prescribing practices, as oncologists become more comfortable integrating biosimilars into treatment regimens, thereby expanding their market presence.
Cost containment pressures within healthcare systems are driving the growth of the Oncology Biosimilars Market. As healthcare costs continue to rise, payers and providers are increasingly seeking ways to reduce expenditures while maintaining quality care. Biosimilars present a viable solution, as they typically offer lower prices compared to their reference biologics. This price differential is particularly appealing in oncology, where treatment regimens can be prohibitively expensive. The Oncology Biosimilars Market is thus positioned to benefit from these economic pressures, as stakeholders prioritize cost-effective therapies to manage budgets and improve patient access to essential treatments.
Technological advancements in biotechnology are transforming the landscape of the Oncology Biosimilars Market. Innovations in biomanufacturing processes and analytical techniques have enhanced the ability to produce high-quality biosimilars that closely mimic their reference biologics. These advancements not only improve the efficacy and safety profiles of biosimilars but also streamline the regulatory approval process. As a result, the Oncology Biosimilars Market is witnessing an influx of new products, which could potentially lead to increased competition and lower prices for patients. The ongoing research and development efforts in this field suggest a promising future for biosimilars in oncology.
The rising incidence of cancer worldwide is a pivotal driver for the Oncology Biosimilars Market. As cancer cases continue to escalate, the demand for effective treatment options intensifies. According to recent statistics, cancer is projected to affect approximately 1 in 5 individuals during their lifetime, leading to a substantial increase in healthcare expenditure. This surge in cancer prevalence necessitates the development and availability of biosimilars, which offer a more affordable alternative to expensive biologic therapies. Consequently, the Oncology Biosimilars Market is likely to experience significant growth as healthcare providers seek cost-effective solutions to manage the increasing patient population.
The evolving regulatory framework surrounding biosimilars is a crucial driver for the Oncology Biosimilars Market. Regulatory agencies are increasingly establishing clear guidelines for the approval and monitoring of biosimilars, which fosters confidence among manufacturers and healthcare providers. These enhancements not only expedite the entry of new biosimilars into the market but also ensure that they meet stringent safety and efficacy standards. As a result, the Oncology Biosimilars Market is likely to see a rise in the number of approved products, thereby expanding treatment options for patients and potentially lowering costs through increased competition.
The shift towards patient-centric treatment approaches is influencing the Oncology Biosimilars Market. As healthcare systems increasingly prioritize personalized medicine, there is a growing recognition of the need for diverse treatment options that cater to individual patient needs. Biosimilars, with their comparable efficacy and safety profiles to reference biologics, are becoming integral to these patient-centric strategies. This trend is expected to enhance the acceptance and utilization of biosimilars among healthcare providers and patients alike. Consequently, the Oncology Biosimilars Market may experience accelerated growth as stakeholders embrace these innovative therapies to improve patient outcomes.
Monoclonal antibodies dominate the Oncology Biosimilars Market, accounting for a significant portion of 54% in the overall share due to their pivotal role in cancer treatment protocols. They are highly regarded for their efficacy in targeting specific cancer cells, leading to favorable therapeutic outcomes. Following closely are proteins and peptides, but it is the peptides that are rapidly gaining traction, appealing to a broader spectrum of patients due to their more favorable side effect profiles and ease of administration. The growth trends of this market segment are largely driven by advancements in biosimilar development and regulatory frameworks that facilitate quicker pathways to market. The increase in cancer prevalence has also catalyzed demand, prompting pharmaceutical companies to invest heavily in research and development of biosimilars. As treatment paradigms evolve, peptides are emerging more prominently, showcasing their potential for innovative therapies, particularly in immunotherapy and personalized medicine.
Amgen (US) continues strengthening its oncology biologics and biosimilars portfolio through sustained R&D investment and commercialization of monoclonal antibody therapies, supporting widespread adoption across global oncology treatment pathways.
In the Oncology Biosimilars Market, the segment of Breast Cancer currently holds the largest share of 37%, reflecting its significant impact on the patient population and treatment landscape. Following closely, Colorectal Cancer is emerging with remarkable growth, driven by an increasing prevalence and advancements in biosimilar therapies. This distribution underscores the urgent need for effective treatment options in diverse subcategories of oncology, thereby influencing market dynamics and strategic investments.
Roche (CH) remains a global leader in breast cancer therapeutics, continuously expanding oncology research and precision medicine programs that reinforce demand for biologics and biosimilars in breast cancer treatment.
In the Oncology Biosimilars Market, the distribution of market share across the various routes of administration demonstrates distinct preferences among healthcare providers. Intravenous administration remains the largest segment holding market share of 65%, primarily due to its well-established efficacy in delivering medications directly into the bloodstream for rapid therapeutic action. Subcutaneous administration, while smaller in market share, is gaining traction rapidly due to its user-friendly nature and potential for at-home administration, driving growth and competition in this space.
Administration Route: Intravenous (Dominant) vs. Subcutaneous (Emerging)
Intravenous administration is characterized by its dominance in the Oncology Biosimilars Market, providing immediate drug delivery and patient monitoring capabilities that are essential in oncology treatments. This route is preferred for patients requiring intensive therapy, especially in acute settings. On the other hand, subcutaneous administration is emerging as a compelling alternative for many oncology treatments, offering advantages such as reduced administration time and increased patient compliance. Its growing acceptance stems from enhanced drug formulations that are easier to self-administer, which can significantly enhance patient convenience and adherence to treatment regimens.
In the Oncology Biosimilars Market, the distribution of market share is prominently led by hospitals with market share of 52%, which cater to a substantial volume of oncology patients and account for a significant portion of biosimilars usage. Specialty clinics, while smaller in terms of share, show a rapid increase in their engagement with biosimilars, driven by a growing number of personalized treatment plans and an increasing focus on targeted therapies. Research laboratories, although crucial for trial and development, do contribute less directly to the end-user market share as compared to the clinical application seen in hospitals and specialty clinics. The growth trends in this segment are shaped by several key drivers. Hospitals continue to adopt biosimilars in oncology for their cost-effectiveness and efficacy, addressing the rising demand for cancer treatments. Conversely, specialty clinics are becoming the fastest-growing segment as they often provide focused care and innovative treatment options. The increasing prevalence of cancer and the patients' need for accessible and affordable therapies further contribute to the growth of both hospitals and specialty clinics in this market.
Hospitals (Dominant) vs. Specialty Clinics (Emerging)
Hospitals play a dominant role in the Oncology Biosimilars Market due to their capacity to treat large patient populations and access to advanced healthcare technologies, enabling them to offer superior cancer care. They benefit from economies of scale and institutional support for biosimilar adoption since these treatments align with their goals of reducing costs while maintaining high standards of care. In contrast, specialty clinics represent an emerging segment that specializes in specific areas of cancer treatment, offering personalized therapeutic options and enhancing patient outcomes. Their growing emphasis on innovative treatment plans and rapid adoption of biosimilars positions them well in the evolving landscape of oncology care, making them a pivotal player in increasing access to biotherapeutics.
Get more detailed insights about Oncology Biosimilars Market Request Free Sample
North America leads in the Oncology Biosimilars Market size, accounting for over 45.71% of the global revenue in 2024. The region's growth is driven by increasing cancer prevalence, rising healthcare costs, and favorable regulatory frameworks that encourage biosimilar adoption. The FDA's streamlined approval processes for biosimilars further catalyze market expansion, making it a hub for innovation and investment in oncology treatments. The United States is the primary player in this market, with significant contributions from Canada. North America’s growth is driven by increasing cancer prevalence, high oncology treatment costs, and favorable biosimilar approval frameworks supporting affordable cancer therapies.
Key players such as Amgen, Pfizer, and Mylan dominate the landscape, leveraging advanced research and development capabilities. The competitive environment is characterized by ongoing collaborations and partnerships aimed at enhancing product offerings and market reach, ensuring that North America remains at the forefront of biosimilar advancements.
GE HealthCare invested approximately USD 1.9 billion in research and development during 2024, supporting continued innovation in oncology imaging, precision diagnostics, and integrated cancer care technologies that complement biosimilar adoption.
Europe Oncology Biosimilars Market size was valued at USD 1.914 Billion in 2024, making it the second-largest regional market with a 35% share. The region benefits from robust regulatory support, with the European Medicines Agency (EMA) actively promoting biosimilar development to enhance patient access to affordable treatments. The increasing incidence of cancer and the need for cost-effective therapies are key drivers of market growth in Europe. Europe’s market expansion is fueled by supportive biosimilar regulations, increasing cancer burden, and strong emphasis on affordable healthcare access.
Leading countries in this region include Germany, France, and the UK, which are home to several prominent biosimilar manufacturers. Companies like Roche and Sandoz are pivotal in shaping the competitive landscape, focusing on innovation and strategic partnerships. The presence of a well-established healthcare infrastructure and supportive policies further bolster the market, making Europe a critical player in the biosimilars in oncology sector.
cancer rates, rising healthcare expenditures, and a growing awareness of biosimilars among healthcare professionals and patients. Regulatory bodies in countries like India and China are also streamlining approval processes, which is expected to enhance market penetration. Key players in this region include Celltrion and Samsung Bioepis, which are making significant strides in biosimilar oncology development.
Countries such as India and China are leading the charge, with a burgeoning pharmaceutical industry that supports biosimilar production. The competitive landscape is evolving, with local companies increasingly collaborating with The Oncology Biosimilars Market presence and product offerings, positioning Asia-Pacific as a vital region for future growth in oncology biosimilars.
The Middle East and Africa represent a resource-rich frontier for the oncology biosimilars market, currently holding about 5% of the global market share. The region's growth is driven by increasing cancer prevalence, rising healthcare investments, and a growing demand for affordable treatment options. However, regulatory challenges and limited awareness of biosimilars hinder faster market development, presenting both challenges and opportunities for stakeholders.
Countries like South Africa and the UAE are emerging as key players in this market, with local biosimilar manufacturers beginning to explore biosimilar production. The competitive landscape is still developing, with international companies looking to enter the market through partnerships and collaborations. As healthcare infrastructure improves and regulatory frameworks evolve, the Middle East and Africa are poised for significant growth in the oncology biosimilars sector.
The Oncology Biosimilars Market is currently characterized by a dynamic competitive landscape, driven by the increasing demand for cost-effective treatment options and the growing prevalence of cancer globally. Major players such as Amgen (US), Roche (CH), and Sandoz (CH) are strategically positioned to leverage their extensive portfolios and research capabilities. Amgen (US) focuses on innovation and expanding its biosimilar offerings, while Roche (CH) emphasizes partnerships to enhance its market reach. Sandoz (CH), a leader in biosimilars, is committed to optimizing its supply chain and manufacturing processes, which collectively shapes a competitive environment that is both collaborative and competitive. Key business tactics in the Oncology Biosimilars Market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several key players exerting influence over various segments. This structure allows for a diverse range of products and strategies, fostering competition that encourages innovation and responsiveness to market needs. In August 2025, Amgen (US) announced a strategic partnership with a leading European healthcare provider to enhance access to its biosimilar portfolio. This collaboration is likely to improve patient access to affordable treatments, thereby reinforcing Amgen's position in the market. The partnership underscores the importance of strategic alliances in expanding market reach and enhancing service delivery. In September 2025, Roche (CH) launched a new biosimilar product aimed at treating a specific type of cancer, which is expected to significantly impact its market share. This move not only diversifies Roche's product offerings but also demonstrates its commitment to addressing unmet medical needs. The introduction of this biosimilar could potentially reshape treatment protocols and enhance patient outcomes, indicating Roche's proactive approach in a competitive landscape. In July 2025, Sandoz (CH) completed the acquisition of a biosimilar manufacturing facility in Asia, which is anticipated to bolster its production capabilities and reduce lead times. This strategic acquisition reflects Sandoz's focus on supply chain optimization and local manufacturing, which are critical in meeting the growing demand for biosimilars in emerging markets. The facility is expected to enhance Sandoz's operational efficiency and responsiveness to market dynamics. As of October 2025, current trends in the Oncology Biosimilars Market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, which will be essential for sustaining market leadership.
The Oncology Biosimilars Market has recently seen significant developments, particularly with companies like Pfizer, Sandoz, and Roche actively pursuing growth opportunities. In September 2023, Pfizer announced the expansion of its oncology portfolio through the introduction of a new biosimilar for a widely-used cancer treatment, further enhancing its market position. Similarly, Sandoz has been making strides in the sector with partnerships aimed at improving access to affordable cancer therapies.
Additionally, Bristol Myers Squibb recently highlighted advancements in their biosimilar offerings, showcasing their commitment to improving patient outcomes. Teva Pharmaceutical Industries and Amgen have also reported growth in market valuations, driven by increasing demand for cost-effective treatment options.
Merger and acquisition activities are notable, with Novartis completing the acquisition of a biosimilar company in August 2023, aimed at bolstering its oncology biosimilars segment. Over the past 2-3 years, the market has witnessed considerable attention with the approval of several critical biosimilars made by companies such as Biocon and Samsung Biologics, which indicate an overall positive trajectory in the industry's evolution and competitive landscape.
The Enteral Feeding Tubes Market size is projected to reach USD 14.4 Billion by 2035, growing at a CAGR of 9.2%, driven by increasing cancer prevalence, cost containment efforts, and regulatory support.
New opportunities lie in:
By 2035, the Oncology Biosimilars Market is expected to achieve substantial growth and innovation.
| MARKET SIZE 2024 | 5.469(USD Billion) |
| MARKET SIZE 2025 | 5.973(USD Billion) |
| MARKET SIZE 2035 | 14.4(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Amgen (US), Roche (CH), Sandoz (CH), Pfizer (US), Boehringer Ingelheim (DE), Mylan (US), Celltrion (KR), Samsung Bioepis (KR), Teva (IL) |
| Segments Covered | Product Type, Therapeutic Area, Route of Administration, End Users, Regional |
| Key Market Opportunities | Emerging regulatory frameworks enhance access to Oncology Biosimilars, driving market growth and patient affordability. |
| Key Market Dynamics | Rising regulatory support and competitive pricing are driving the adoption of oncology biosimilars in therapeutic markets. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
The Oncology Biosimilars Market is projected to reach a valuation of 14.4 USD Billion by 2035.
In 2024, the Oncology Biosimilars Market was valued at 5.469 USD Billion.
The expected CAGR for the Oncology Biosimilars Market during the forecast period 2025 - 2035 is 9.2%.
Leukemia is expected to show the highest growth, with a projected increase from 1.5 USD Billion to 4.2 USD Billion.
Key segments include Monoclonal Antibodies, Proteins, Peptides, and Vaccines.
Key players in the market include Amgen, Roche, Sandoz, Pfizer, and Boehringer Ingelheim.
The market size for Monoclonal Antibodies is projected to grow from 2.5 USD Billion to 6.0 USD Billion by 2035.
The route of administration, particularly Intravenous, is projected to grow from 2.183 USD Billion to 5.76 USD Billion by 2035.
The market size for specialty clinics is expected to increase from 1.639 USD Billion to 4.2 USD Billion by 2035.
Trends such as increasing cancer prevalence and advancements in biosimilar technology are likely to drive market growth.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO) International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), International Generic and Biosimilar Medicines Association (IGBA), World Health Organization (WHO) Global Health Observatory, IQVIA Institute for Human Data Science, Evaluate Pharma, and national health ministry reports from key markets. These sources were used to collect cancer incidence statistics, regulatory approval data, clinical safety and efficacy studies, pricing trends, and competitive landscape analysis for monoclonal antibodies, therapeutic proteins, peptides, and vaccine-based biosimilars across breast cancer, colorectal cancer, non-small cell lung cancer, and leukemia indications.
In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from cancer biosimilar producers, reference biologic originators, and contract manufacturing organizations (CMOs) were examples of supply-side sources. Board-certified oncologists, hematologists, hospital pharmacy directors, procurement leads from oncology centers, managers of specialty clinics, and formulary decision-makers from hospital systems and payer organizations were examples of demand-side sources. In addition to gathering information on clinical adoption patterns, pricing strategies, interchangeability policies, and reimbursement dynamics, primary research verified product pipeline timings and validated market segmentation.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)
Global market valuation was derived through revenue
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
